Warenius, Hilmar M.Kilburn, Jeremy DEssex, Jon W.Maurer, Richard I.Blaydes, Jeremy P.Agarwala, UshaSeabra, Laurence A.2019-04-222019-04-222011-06-13Warenius, H M, Kilburn, J D, Essex, J W, Maurer, R I, Blaydes, J P, Agarwala, U & Seabra, L A 2011, 'Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4', Molecular Cancer, vol. 10, 72. https://doi.org/10.1186/1476-4598-10-721476-4598http://hdl.handle.net/2164/12198We are grateful to Mikhail Lomosonov for Western blotting of Cdk1/Cdk4 in RT112 cells, Bill Primrose (Theryte Ltd) for designing THR79, Kyla Grimshaw (Horizon Discovery Services, 260 Cambridge Science Park, Milton Road, Cambridge, CB4 0WE) for some of the clonogenic assays and photomicrography, Kyla Grimshaw and John Goodall for carrying out sulphorhodamine, Alamar Blue, Cell Titre-Glo and autophagy assays and Amanda Howarth for data analysis and preparation of figures. This work was supported by the Cancer and Polio Research Fund, Hoylake, Wirral, UK and Theryte Ltd., William Russell House, The Square, Lightwater, Surrey, GU18 5SS, UK.166243952engSDG 3 - Good Health and Well-beingCdk4non-kinaseproteomicPRGPRPprogrammed cell deathselective anticancerbroad spectrumSKIN TUMOR-DEVELOPMENTHUMAN CANCER-CELLSIN-VITROKERATINOCYTE PROLIFERATIONCDK4PROTEINASSAYCOEXPRESSIONACTIVATIONPREDICTIONR MedicineRJournal article10.1186/1476-4598-10-7210